{"id":"cyclosporine-injection-iv","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Nephrotoxicity/renal dysfunction"},{"rate":"25-50","effect":"Hypertension"},{"rate":"10-25","effect":"Tremor"},{"rate":"10-30","effect":"Gingival hyperplasia"},{"rate":"10-25","effect":"Hirsutism"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Hyperkalemia"},{"rate":"20-40","effect":"Infection"},{"rate":"1-5","effect":"Neurotoxicity (encephalopathy)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response, making it a potent immunosuppressant used to prevent organ rejection and treat autoimmune conditions.","oneSentence":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:06.747Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)"},{"name":"Severe rheumatoid arthritis"},{"name":"Severe psoriasis"},{"name":"Nephrotic syndrome"},{"name":"Autoimmune uveitis"}]},"trialDetails":[{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06790095","phase":"PHASE2","title":"TRACK-TBI Precision Medicine Part 3 - Option II","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":"Traumatic Brain Injury","enrollment":26},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT05398653","phase":"PHASE1, PHASE2","title":"A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy","status":"COMPLETED","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2022-02-24","conditions":"Primary Membranous Nephropathy","enrollment":94},{"nctId":"NCT05862233","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2023-06-02","conditions":"Primary Membranous Nephropathy","enrollment":150},{"nctId":"NCT05867329","phase":"PHASE4","title":"Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2023-09-30","conditions":"Ulcerative Colitis Acute","enrollment":162},{"nctId":"NCT05789615","phase":"","title":"Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"CMV Infection, Hematopoietic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT03079089","phase":"NA","title":"Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2017-06-30","conditions":"Refractory or Relapsed Lymphoid Haemopathy","enrollment":40},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT03035422","phase":"NA","title":"Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2018-01-15","conditions":"Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT02462252","phase":"PHASE2","title":"Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2015-10","conditions":"Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome","enrollment":11},{"nctId":"NCT02167958","phase":"PHASE1","title":"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","status":"COMPLETED","sponsor":"Rafic Farah, MD","startDate":"2015-02-11","conditions":"Leukemia, MDS, Myelofibrosis","enrollment":28},{"nctId":"NCT01527240","phase":"PHASE2","title":"Neuroprotection Impact of Cyclosporin A in Cerebral Infarction","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-10","conditions":"Stroke","enrollment":126},{"nctId":"NCT00249808","phase":"PHASE4","title":"A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-12-13","conditions":"Psoriasis","enrollment":1266},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT02904772","phase":"PHASE2","title":"Alipogene Tiparvovec for the Treatment of LPLD Patients","status":"WITHDRAWN","sponsor":"UniQure Biopharma B.V.","startDate":"2016-10","conditions":"LPL Deficiency","enrollment":""},{"nctId":"NCT00639717","phase":"PHASE2","title":"Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-03","conditions":"Graft Versus Host Disease","enrollment":48},{"nctId":"NCT01650662","phase":"PHASE3","title":"CYCLosporinE A in Reperfused Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2012-01","conditions":"Acute Myocardial Infarction","enrollment":410},{"nctId":"NCT01817322","phase":"PHASE4","title":"Kidney Graft Function Under the Immunosuppression Strategies","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-06","conditions":"Chronic Renal Disease","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sandimmune"],"phase":"marketed","status":"active","brandName":"Cyclosporine Injection (IV)","genericName":"Cyclosporine Injection (IV)","companyName":"Berinstein, Jeffrey","companyId":"berinstein-jeffrey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Severe rheumatoid arthritis, Severe psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}